PMID- 28364477
OWN - NLM
STAT- MEDLINE
DCOM- 20170906
LR  - 20190318
IS  - 1550-9109 (Electronic)
IS  - 0161-8105 (Print)
IS  - 0161-8105 (Linking)
VI  - 40
IP  - 1
DP  - 2017 Jan 1
TI  - Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine 
      in Narcolepsy.
LID - 10.1093/sleep/zsw010 [doi]
LID - zsw010
AB  - STUDY OBJECTIVES: To follow the temporal changes of cerebrospinal fluid (CSF) 
      biomarker levels in narcoleptic patients with unexpected hypocretin level at 
      referral. METHODS: From 2007 to 2015, 170 human leukocyte antigen (HLA) 
      DQB1*06:02-positive patients with primary narcolepsy and definite (n = 155, 95 
      males, 60 females, 36 children) or atypical cataplexy (n = 15, 4 males, 3 
      children) were referred to our center. Cerebrospinal hypocretin deficiency was 
      found in 95.5% and 20% of patients with definitive and atypical cataplexy, 
      respectively. CSF hypocretin-1 (n = 6) and histamine/tele-methylhistamine (n = 5) 
      levels were assessed twice (median interval: 14.4 months) in four patients with 
      definite and in two with atypical cataplexy and hypocretin level greater than 100 
      pg/mL at baseline. RESULTS: CSF hypocretin levels decreased from 
      normal/intermediate to undetectable levels in three of the four patients with 
      definite cataplexy and remained stable in the other (>250 pg/mL). Hypocretin 
      level decreased from 106 to 27 pg/mL in one patient with atypical cataplexy, and 
      remained stable in the other (101 and 106 pg/mL). CSF histamine and 
      tele-methylhistamine levels remained stable, but for one patient showing 
      increased frequency of cataplexy and a strong decrease (-72.5%) of 
      tele-methylhistamine levels several years after disease onset. No significant 
      association was found between relative or absolute change in hypocretin level and 
      demographic/clinical features. CONCLUSIONS: These findings show that in few 
      patients with narcolepsy with cataplexy, symptoms and CSF marker levels can 
      change over time. In these rare patients with cataplexy without baseline 
      hypocretin deficiency, CSF markers should be monitored over time with potential 
      for immune therapies in early stages to try limiting hypocretin neuron loss.
CI  - (c) Sleep Research Society 2017. Published by Oxford University Press [on behalf of 
      the Sleep Research Society].
FAU - Lopez, Regis
AU  - Lopez R
AD  - Unite des Troubles du Sommeil Service de Neurologie, Centre National de Reference 
      Narcolepsie Hypersomnies, Hopital Gui-de-Chauliac, Montpellier F-34000, France.
AD  - Inserm U1061, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
FAU - Barateau, Lucie
AU  - Barateau L
AD  - Unite des Troubles du Sommeil Service de Neurologie, Centre National de Reference 
      Narcolepsie Hypersomnies, Hopital Gui-de-Chauliac, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
FAU - Evangelista, Elisa
AU  - Evangelista E
AD  - Unite des Troubles du Sommeil Service de Neurologie, Centre National de Reference 
      Narcolepsie Hypersomnies, Hopital Gui-de-Chauliac, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
FAU - Chenini, Sofiene
AU  - Chenini S
AD  - Unite des Troubles du Sommeil Service de Neurologie, Centre National de Reference 
      Narcolepsie Hypersomnies, Hopital Gui-de-Chauliac, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
FAU - Robert, Philippe
AU  - Robert P
AD  - Bioprojet-Biotech, Saint Gregoire F-35760, France.
FAU - Jaussent, Isabelle
AU  - Jaussent I
AD  - Inserm U1061, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
FAU - Dauvilliers, Yves
AU  - Dauvilliers Y
AD  - Unite des Troubles du Sommeil Service de Neurologie, Centre National de Reference 
      Narcolepsie Hypersomnies, Hopital Gui-de-Chauliac, Montpellier F-34000, France.
AD  - Inserm U1061, Montpellier F-34000, France.
AD  - Universite de Montpellier, Montpellier F-34000, France.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Sleep
JT  - Sleep
JID - 7809084
RN  - 0 (Biomarkers)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (Methylhistamines)
RN  - 0 (Orexins)
RN  - 820484N8I3 (Histamine)
RN  - KCB81T4EOF (tele-methylhistamine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Biomarkers/cerebrospinal fluid
MH  - Cataplexy/cerebrospinal fluid
MH  - Child
MH  - Female
MH  - HLA-DQ beta-Chains/immunology
MH  - Histamine/*cerebrospinal fluid
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Methylhistamines/cerebrospinal fluid
MH  - Middle Aged
MH  - Narcolepsy/*cerebrospinal fluid
MH  - Orexins/*cerebrospinal fluid/deficiency
MH  - Time Factors
PMC - PMC5806580
OTO - NOTNLM
OT  - *cataplexy
OT  - *histamine.
OT  - *hypocretin/orexin
OT  - *narcolepsy
EDAT- 2017/04/02 06:00
MHDA- 2017/09/07 06:00
PMCR- 2017/02/09
CRDT- 2017/04/02 06:00
PHST- 2017/04/02 06:00 [entrez]
PHST- 2017/04/02 06:00 [pubmed]
PHST- 2017/09/07 06:00 [medline]
PHST- 2017/02/09 00:00 [pmc-release]
AID - 2979189 [pii]
AID - zsw010 [pii]
AID - 10.1093/sleep/zsw010 [doi]
PST - ppublish
SO  - Sleep. 2017 Jan 1;40(1):zsw010. doi: 10.1093/sleep/zsw010.